PD-1 blockade prompts CD8+ T cell differentiation (136); CTLA-4 blockade solves restrictions on T cell priming and activation (25); ACT may bypass limitations on T cell priming and expansion (137); OV therapy mediates new T cell priming and activation by lysing tumor cells to release tumor-associated antigens (138). This evidence concerns the gene CTLA4 and neoplasm.